GeneTether Therapeutics (GeneTether Therapeutics) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is GeneTether Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. GeneTether Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, GeneTether Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for GeneTether Therapeutics's Cash-to-Debt or its related term are showing as below:

GNTTF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.37 Med: No Debt Max: No Debt
Current: No Debt

During the past 4 years, GeneTether Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.37. And the median was No Debt.

GNTTF's Cash-to-Debt is ranked better than
99.8% of 1527 companies
in the Biotechnology industry
Industry Median: 6.42 vs GNTTF: No Debt

GeneTether Therapeutics Cash-to-Debt Historical Data

The historical data trend for GeneTether Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

GeneTether Therapeutics Cash-to-Debt Chart

GeneTether Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

0.37

No Debt

GeneTether Therapeutics Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial								No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of GeneTether Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, GeneTether Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GeneTether Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GeneTether Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where GeneTether Therapeutics's Cash-to-Debt falls into.

GeneTether Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

GeneTether Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

GeneTether Therapeutics had no debt ⁽¹⁾.

GeneTether Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

GeneTether Therapeutics had no debt ⁽¹⁾.

GeneTether Therapeutics (OTCPK:GNTTF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

GeneTether Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of GeneTether Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

GeneTether Therapeutics (GeneTether Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneTether Therapeutics Inc (OTCPK:GNTTF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

GTTX:Canada

Address

301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, V1Y 2B3

Website

https://www.genetether.com

GeneTether Therapeutics Inc is a genetic medicines company focused on the development of high-efficiency precision gene editing for human therapeutics applications. It is engaged in creating gene-editing therapies based on the proprietary GeneTether platform. Further, it is focused on building a discovery pipeline for the treatment of rare, monogenic diseases of the kidney and the skin.

GeneTether Therapeutics (GeneTether Therapeutics) Headlines

From GuruFocus

The Power Play by The Market Herald Releases New Interview with GeneTether Therapeutics

By ACCESSWIRE ACCESSWIRE • 05-31-2022

GeneTether Therapeutics (GeneTether Therapeutics) Cash-to-Debt : No Debt (1) (As of Dec. 2023)